Cemiplimab Monotherapy and Five-Year Outcomes in Advanced Non-Small Cell Lung Cancer: Results and Implications

home / between-the-lines / cemiplimab-monotherapy-and-5-year-outcomes-in-advanced-non-small-cell-lung-cancer-results-and

Eric K. Singhi, M.D.,and ​Ben Creelan, M.D., discuss how over the past 5 years, PD-1 inhibitors have reshaped first-line therapy for advanced non-small cell lung cancer (NSCLC), improving survival outcomes. Biomarkers like PD-L1 and patient characteristics guide treatment choices. New data on cemiplimab enhances decision-making, balancing efficacy with quality of life.

© 2025 MJH Life Sciences

All rights reserved.